Tuesday, September 29 – New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, found no link between semaglutide use and pancreatic cancer in nationwide registry data from Denmark, Sweden and Norway. The regulator-mandated post-authorization study was presented by Anton Pottegård, a professor at the University of Southern Denmark in Odense, and colleagues.

Tuesday, September 29 – The number of people using GLP-1 treatments like Ozempic and Wegovy for weight loss or chronic conditions has increased rapidly, with more than 1 in 10 U.S. adults currently taking such medications. A new study led by medical students at Virginia Commonwealth University has shed light on how this rise in GLP-1 drug use is affecting Americans’ wallets.

Tuesday, September 29 – Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being marketed as a way to look and feel better

Tuesday, September 29 – Blockbuster GLP-1 drugs have transformed the lives of millions of people. Lately, they’re undergoing a makeover of their own.

Monday, September 28 – New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, makes a case for extending the indication for GLP-1 receptor agonists (GLP1-RAs) to millions more people to protect their heart health.

Monday, September 28 – Experts share what you need to know about GLP-1-related hair loss as the side-effect gets more attention from researchers About 20 million people across the US, UK, and EU are taking GLP-1 receptor agonists like tirzepatide and semaglutide (Ozempic or Mounjaro are common brands) for weight loss and type 2 diabetes. As their use has surged, we’re learning more about their side-effects. One that’s been getting a lot of attention from researchers lately: hair loss.In one survey of people who take these medications, 20% of respondents experienced hair shedding, although the lack of high-quality data from a randomized, controlled trial to assess this side-effect makes it difficult to know exactly how common it is. Continue reading…

Sunday, September 27 – New analyses to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, show that orforglipron, a daily oral medication for weight loss and type 2 diabetes, was associated with similar weight loss among women of different ages and at different life stages: before, during and after menopause.

Sunday, September 27 – Tirzepatide, sold as Mounjaro and Zepbound, activated calorie-burning brown fat in obese mice, revealing a potential metabolic effect beyond appetite suppression. If confirmed in humans, the finding could help explain the drug’s powerful benefits and inspire more comprehensive treatments for obesity and diabetes.

Saturday, September 26 – Chipotle, McDonald’s and Shake Shack are among the restaurant chains revamping their menus as more consumers go on weight-loss drugs.

Saturday, September 26 – Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a reported 5-year survival rate of approximately 13.3%, largely because of late diagnosis, rapid progression and resistance to treatment. GAIP-interacting protein C terminus 1 (GIPC1), overexpressed in PDAC, is a scaffolding protein that stabilizes multiple oncogenic receptors and signaling complexes involved in proliferation, survival, adhesion, migration and chemoresistance.

Friday, September 25 – Mylan Pharmaceuticals Inc. has launched a lawsuit in Delaware federal court asking for a finding that its proposed generic version of Novo Nordisk Inc.’s blockbuster weight loss drug Wegovy does not infringe a patent, the latest salvo in a larger intellectual property fight over the GLP-1.

Friday, September 25 – FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s semaglutide “regularly or in inordinate amounts” at a site with “insanitary conditions.”

Friday, September 25 – People taking popular GLP-1 medications such as Ozempic, Wegovy and Zepbound may face stigma from those closest to them, according to a new study by a Florida State University professor.

Friday, September 25 – Children taking GLP-1 medications (such as Victoza, Saxenda, Trulicity, and Ozempic) for weight loss, prediabetes, or type 2 diabetes may face an overlooked risk: nutritional deficiencies. A new study found that nearly 1 in 6 young patients developed a diagnosed deficiency within a year of starting treatment, with vitamin D deficiency affecting about 12%.

Thursday, September 24 – Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal suggests that this effect cannot be entirely explained by patients losing weight on the drug.

Thursday, September 24 – (MedPage Today) — The FDA issued a warning letter this month to Empower Pharmacy over its mass production of compounded GLP-1 weight-loss and diabetes drugs, citing illegal copycat manufacturing and insanitary conditions.
Following a facility…

Thursday, September 24 – Woman who used semaglutide and lost vision is among people suing the makers of GLP-1 weight-loss drugs for not being warned about potential vision loss.

Wednesday, September 23 – Viking Therapeutics’ VK2735 met Truist’s “best-case scenario,” with robust weight loss that was largely maintained when patients transitioned to less frequent dosing. Viking’s stock popped more than 30% on Tuesday.

Wednesday, September 23 – With sales of the oral GLP-1 medicine rising quickly, executives reassured investors that Novo has secured production capacity to support continued growth.

Wednesday, September 23 – With a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the Psych Congress 2026, the company presented early-stage data that could support the potential of its next-gen GLP-1 and GIP receptor agonist to treat diseases far beyond obesity.

Wednesday, September 23 – (MedPage Today) — Note that some links may require registration or subscription.
Dozens of Americans sued manufacturers of GLP-1 receptor agonists, claiming the drugmakers failed to warn patients about the risk of non-arteritic anterior ischemic…

Wednesday, September 23 – The mid-stage readout is one link in a chain of catalysts that analysts were watching for this year from Roche’s metabolic pipeline, which features assets from the $2.7 billion acquisition of Carmot Therapeutics as well as partner Zealand Pharma.

Wednesday, September 23 – Heidi Skolnik, a sports nutritionist, exercise physiologist and bestselling author, joins TODAY to discuss her latest book, “Your GLP-1 Game Plan,” that is filled with guidance on what to eat and how to move and thrive on weight loss medications. “The medication doesn’t give you nourishment, and it doesn’t give you strength. You really need to go beyond the scale to think about your ‘why.’ And we know that when you focus on health beyond appearance, you do better,” she says.

Wednesday, September 22 – About 11% of Americans are taking a GLP-1 medication, up considerably from 3% in 2024, according to a recent Gallup poll.

Tuesday. September 22 – Hundreds of Americans are suing GLP-1 drugmakers Novo Nordisk and Ely Lilly, saying they were not adequately warned of the potential danger of vision loss. In statements, Novo Nordisk says, in part, they are “vigorously” fighting the lawsuits, saying they are “without merit,” while Eli Lilly says in part, it maintains “patient safety” is its “top priority.” NBC News’ Stephanie Gosk has the story.

Tuesday. September 22 – Children prescribed GLP-1 medications for weight loss, prediabetes or type 2 diabetes are at risk for nutritional deficiencies—diagnosed in nearly one in six patients (16.8%) within the first year—according to a new study published in the journal Childhood Obesity. Vitamin D deficiency was the most common, identified in 12.4% of children within one year of GLP-1 treatment.

Tuesday, September 22 – GLP-1 drugs have revolutionized obesity treatment, but they can lead people to lose muscle mass along with fat. And when patients stop treatment, they often regain their weight—primarily as fat.

Tuesday, September 22 – A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compared with those who stayed on them.

Saturday, September 19 – Research shows that microdosing GLP-1 medications may still lead to weight loss. Tatsiana Volkava · Moment/Getty

Recent research suggests that people may still lose weight while staying on the lowest starting doses of GLP-1 medications, such as Wegovy or Zepbound, for longer periods.

After one year, people taking sustained low dose tirzepatide lost about 5.5% of their body weight, while those taking sustained low dose semaglutide lost about 2.2%.

Lower doses were associated with more modest weight loss than higher doses, but sustained low dose semaglutide was also associated with lower rates of some side effects.

Saturday, September 19 – (MedPage Today) — Frailty did not appear to prevent adults with cardiovascular disease and overweight or obesity from reaping the benefits of semaglutide (Wegovy), a secondary analysis of SELECT trial data indicated.
By week 104, semaglutide…

Saturday, September 19 – Ozempic and other GLP-1 medications can improve blood sugar, weight, and cardiovascular health, but researchers found little evidence that they also improve mental health, employment, marriage, or overall well-being. The findings suggest the drugs’ broader life effects may be subtler than their dramatic physical health benefits.

Friday, September 18 – Millions of people worldwide—as many as 1 in 8 adults in the U.S.—are taking GLP-1 medications, such as Ozempic, Mounjaro, Wegovy and Zepbound, to treat diabetes or for weight loss.

Thursday, September 17 – Retatrutide, an experimental weight loss drug still undergoing clinical trials at Eli Lily, is being marketed online and illegally sold to U.S. clients, a CBS News investigation found. CBS News investigative reporter and producer Daniel Gilbert has the story.

An Illinois federal judge is weighing whether the state’s genetic privacy law protects against disclosing information about people who have taken genetic tests, with a DNA testing company accused of unlawfully sharing such information with Google arguing Wednesday the statute applies only to disclosure of actual test results.

Thursday, September 17 – Elvinix Inc. has announced an exclusive license agreement with Zealand Pharma A/S granting Elvinix the rights to develop and commercialize Zealand’s GLP-1/gastrin dual-agonist peptide portfolio.

Wednesday, September 16 – (MedPage Today) — An international consensus panel outlined the first clinical framework for implementing general-population screening for islet autoantibodies to catch early-stage type 1 diabetes. (Diabetologia)
Another international consensus…

Tuesday, September 15 – (MedPage Today) — Blockbuster GLP-1 receptor agonists revolutionized obesity management in recent years, driving weight loss of up to 20%.
This weight loss, however, can carry a notable downside: Studies estimate that 15% to 40% of GLP-1-induced…

Tuesday, September 15 – The one health care policy Republicans agree on, and a look at how rural providers are approaching AI.

Monday, September 14 – A study linked 15 cases of Wernicke encephalopathy to GLP-1 drugs like Ozempic and Mounjaro, raising concerns about vitamin B1 deficiency risks.

AI analysis of 400,000 Reddit posts found that users of drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound reported unexpected symptoms including menstrual changes, chills, hot flashes, and fatigue. Researchers cannot say the medications caused these problems, but the patterns may reveal overlooked signals worth studying.